furosemide has been researched along with anacardic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balzano, AL; Castellano, S; Feoli, A; La Pietra, V; Mai, A; Marinelli, L; Milite, C; Novellino, E; Sasaki, K; Sbardella, G; Tosco, A | 1 |
| Angeloni, C; Bartolini, M; Bergamini, C; Bolognesi, ML; Chantegreil, F; de Camargo Nascente, L; de Melo Viana Teixeira, S; Freschi, M; Hrelia, S; Malaguti, M; Nachon, F; Prchal, L; Rossi, M; Salerno, A; Soares Romeiro, LA; Soukup, O | 1 |
2 other study(ies) available for furosemide and anacardic acid
| Article | Year |
|---|---|
A novel cell-permeable, selective, and noncompetitive inhibitor of KAT3 histone acetyltransferases from a combined molecular pruning/classical isosterism approach.
Topics: Acetylation; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Histones; Humans; Leukemia; Lysine; Models, Molecular; p300-CBP Transcription Factors | 2015 |
Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Anacardium; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cell Line; Cell Survival; Cytokines; Drug Design; Humans; Ligands; Lipopolysaccharides; Microglia; Molecular Dynamics Simulation; Neuroprotective Agents; Nuts; Plant Extracts; Structure-Activity Relationship; Tacrine | 2021 |